FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...

Scientific publicationFormycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of ...

Biocon said that the European Commission has granted marketing authorisation in the European Union (EU) for Biocon Biologics' Ustekinumab biosimilar 'YESINTEK'.

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Biologics Ltd (BBL), a subsidiary of Biocon Limited, has secured a major regulatory milestone with the European Commission ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

Formycon’s shares edged up 2.4% to 30.60 euros as it revealed it is presenting an overview of the comparative data of the ...

Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants ...